Altium Capital Management LP recently announced the acquisition of new stake in AIkido Pharma Inc. (NASDAQ:AIKI). This fresh investment now brings its stake to 5.73% valued currently at $2.22 million. In addition, Sabby Capital LLC raised its holdings by 0.34 million to 0.34 million shares.
With over 1.01 million AIkido Pharma Inc. (AIKI) shares trading Monday and a closing price of $0.64 on the day, the dollar volume was approximately $0.64 million. The shares have shown a negative weekly performance of -5.71% and its price on 08/31/20 lost nearly -6.32%. Currently, there are 32.98M common shares owned by the public and among those 32.95M shares have been available to trade.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in AIkido Pharma Inc. are Vanguard Extended Market Index Fu, USAA Extended Market Index Fund, and Fidelity Nasdaq Composite Index F. Vanguard Extended Market Index Fu owns 0.1 million shares of the company’s stock, all valued at over $0.11 million. The company bought an additional 80300.0 shares recently to bring their total holdings to about 0.29% of the shares outstanding. USAA Extended Market Index Fund bought 2971.0 shares to see its total holdings expand to 5226.0 shares valued at over $5801.0 and representing 0.02% of the shares outstanding. Fidelity Nasdaq Composite Index F now owns shares totaling to 0.01% of the shares outstanding.
Shares of AIkido Pharma Inc. (NASDAQ: AIKI) opened at $0.67, down -$0.01 from a prior closing price of $0.68. However, the script later closed the day at $0.64, down -6.32%. The company’s stock has a 5-day price change of -5.71% and -8.42% over the past three months. AIKI shares are trading -51.04% year to date (YTD), with the 12-month market performance down to -64.81% lower. It has a 12-month low price of $0.47 and touched a high of $5.46 over the same period. Currently, 1.01 million shares have been traded, compared to an average intraday trading volume of 4.47 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -28.60%, -31.31%, and -34.16% respectively.
Institutional ownership of AIkido Pharma Inc. (NASDAQ: AIKI) shares accounts for 13.30% of the company’s 32.98M shares outstanding. Mutual fund holders own 0.32%, while other institutional holders and individual stakeholders account for 7.25% and — respectively.
It has a market capitalization of $21.55M and a beta (3y monthly) value of 1.90. The earnings-per-share (ttm) stands at -$2.07. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.45% over the week and 10.35% over the month.
Analysts forecast that AIkido Pharma Inc. (AIKI) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and $0 for 2014. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0.